Exciting advancements in understanding and treating inherited retinal diseases (IRDs) are offering new hope for patients and families. Recent research has shed light on the genetic connections between conditions like retinitis pigmentosa (RP) and macular degeneration, while a promising optogenetic therapy for RP has demonstrated durable vision gains over three years.
Unraveling the Genetic Links: RP and Macular Degeneration
Researchers at the University of Houston have identified a crucial link between retinitis pigmentosa and various forms of macular degeneration: the peripherin2 (PRPH2) protein. Both RP and macular degeneration are genetic disorders that lead to vision loss, and until recently, the precise connections between them were not fully understood.
Muna Naash and Muayyad Al Ubaidi, biomedical engineering professors at the University of Houston, are investigating how mutations in the PRPH2 gene contribute to a spectrum of retinal diseases, including RP, cone-rod dystrophy, and multiple forms of macular dystrophy. When healthy, PRPH2 is vital for the structure and function of the photoreceptor outer segments in the retina. Rod photoreceptors, responsible for low-light vision, are damaged in RP, while cone photoreceptors, essential for color vision, degenerate in macular degeneration.
The team's work, supported by a significant grant from the National Eye Institute, aims to understand how different PRPH2 mutations lead to varying disease outcomes and how to potentially shift severe phenotypes to milder ones. Intriguingly, earlier research by Naash indicated that by modulating the ratio of PRPH2 and its partner protein, ROM1, it might be possible to convert more severe macular degeneration phenotypes to the less aggressive RP phenotype. This research underscores the complex interplay of genes and proteins in IRDs and opens new avenues for therapeutic development.
Sustained Vision Improvement with Optogenetic Therapy for Retinitis Pigmentosa
In a significant development for patients with advanced retinitis pigmentosa, Nanoscope Therapeutics' MCO-010 optogenetic therapy has shown sustained and clinically meaningful vision gains over three years. This groundbreaking therapy, which is gene-agnostic, offers hope to individuals regardless of their specific genetic mutation causing RP.
The MCO-010 therapy works by delivering a proprietary multi-characteristic opsin (MCO) transgene via an adeno-associated virus (AAV) into the retina. This opsin sensitizes remaining bipolar cells to light, effectively bypassing the degenerated photoreceptors and restoring light sensitivity to the retina. Unlike traditional gene therapies that correct specific genetic defects, MCO-010 targets downstream retinal neurons, making it applicable across various forms of RP and potentially other retinal degenerations where photoreceptor loss is a common pathway.
Results from the REMAIN study, a long-term extension of the Phase 2b/3 RESTORE trial, demonstrated that patients receiving a single intravitreal injection of MCO-010 maintained an average gain of approximately 0.3 LogMAR in Best Corrected Visual Acuity (BCVA) from baseline through 152 weeks. This is equivalent to an improvement of three lines or 15 letters on a standard ETDRS vision chart. Importantly, the therapy exhibited a favorable safety profile with no serious ocular adverse events. These sustained gains are particularly remarkable given that RP patients typically experience a loss of about 1.5 lines of vision every five years.
Nanoscope Therapeutics has initiated a rolling Biologics License Application (BLA) with the FDA for MCO-010, aiming for it to be the first FDA-approved optogenetic therapy for retinal disease. This represents a significant therapeutic advance, offering a potential treatment option for patients with severe vision loss who currently have limited choices.
A Future of Expanding Treatments
These developments highlight a dynamic period in IRD research. The deeper understanding of genetic links between different retinal diseases, exemplified by the PRPH2 research, could lead to broader therapeutic strategies. Concurrently, the long-term success of optogenetic therapies like MCO-010 demonstrates the potential for gene-agnostic approaches to restore vision, moving beyond gene-specific corrections. As research continues to advance, the landscape of treatment options for inherited retinal diseases is rapidly expanding, offering renewed hope for preserving and restoring sight.